Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | ADCY1 | Q08828 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033611 | 0.90 | ADORA2A (0.47) | ADORA2AADORA1ADCY1KDM4ELMNA | |
| SCHEMBL5036593 | 0.87 | ADORA2A (0.45) | ADORA2AADORA1ADCY1KDM4ELMNA | |
| SCHEMBL5033620 | 0.87 | ADORA2A (0.45) | ADORA2AADORA1ADCY1KDM4ELMNA | |
| SCHEMBL5037699 | 0.86 | ADCY1 (0.51) | ADORA2AADORA1ADCY1KDM4ELMNA | |
| SCHEMBL5036764 | 0.83 | ADORA2A (0.70) | ADORA2AADORA1MAPTMAPK1ALDH1A1 | |
| SCHEMBL5033953 | 0.83 | ADORA2A (0.47) | ADORA2AADORA1MAPTMAPK1ALDH1A1 | |
| SCHEMBL5036500 | 0.82 | HTT (0.54) | ADORA2AADORA1ADCY1KDM4ELMNA | |
| SCHEMBL5033495 | 0.81 | ADCY1 (0.42) | ADORA2AADORA1ADCY1KDM4ELMNA | |
| SCHEMBL5037843 | 0.81 | ADORA2A (0.53) | ADORA2AADORA1MAPTMAPK1ALDH1A1 | |
| SCHEMBL5037899 | 0.81 | ADCY1 (0.44) | ADORA2AADORA1ADCY1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1587799-B1 | BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-6992083-B2 | deiodination/arylation, acylation or hydrogenation of a substituted 4-methoxy-bezoxazole derivative; adenosine receptor ligands; Parkinson's and Alzheimer's Diseases; 2-Chloromethyl-N-[7-(4-fluoro-phenyl)-4-methoxy-benzooxazol-2-yl]-isonicotinamide | HOFFMAN-LA ROCHE INC. (US) | 2006-01-31 | — | — | US | disclosed |
| EP-1587799-A1 | BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-26 | — | — | EP | disclosed |
| US-20040152702-A1 | Benzoxazol derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-05 | — | — | US | disclosed |
| WO-2004063177-A1 | BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152702-A1 | Benzoxazol derivatives | P2RX3, P2RX2, P2RX1 | ADORA2A 11/4885ADORA1 8/4885ADCY1 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.